Y-biologics Inc.

Korea Research Institute of Bioscience and Biotechnology

Yonsei University

A&rt Co., Ltd.

Medpacto Inc.

Metabolic Engineering Laboratories Co., Ltd.

Antibody and Receptor Therapeutics Co., Ltd.

Seoul National University

Biocomplete Inc.

Seok Ho Yoo

Young Woo Park

Bum-chan Park

Jae Eun Park

Hye Nan Kim

Myeoung Hee Jang

Dong Hee Lee

Young-Gyu Cho

Ki Won Jo

Jung Chae Lim

Gi Sun Baek

Youngja Song

Yeung Chul Kim

Chan Woong Park

Sunha Yoon

Sang Pil Lee

Seon Ha Yun

Ji-Young Shin

Yunseon Choi

Eun Young Lee

Yong Ho Lee

Eun Bong Lee

Dong Jin Kim

Ji Su Lee

Seil Jang

Hyun Ju Lee

Kyu Won Cho

Joong Kyu Kim

Yeong Wook Song

Il Ho Ha

Si Hyung Lee

Myeong Hee Jang

Soon Sil Hyun

Jisu Lee

Sun Jeong Jo

Gisun Baek

Eun Young Jeon

Yeung-Chul Kim

Dong Jung Lee

Bum Chan Park

Ju Ry Lim

Bong-soo Cha

Ki Chul Shin

Heun-Soo Kang

So-Hyun Park

Mi Ra Park

Ke Se Lee

Kyung Jin Kim

A bispecific antibody according to an embodiment of the present disclosure specifically binds to IL-17A and TNF-α. The bispecific antibody according to the present invention or an antigen binding fragment thereof exhibits high specificity for IL-17A and TNF-α and more favorable neutralization property compared to monospecific antibody of a prior art, and, by quickly suppressing inflammation and an immune response by inhibiting simultaneously IL-17 and TNF-α, it has an advantage of improving the treatment effect with lower dose.

Bispecific antibody specifically binding to IL-17A and TNF-α

A monoclonal antibody or an antigen-binding fragment thereof according to an embodiment of the present invention can bind to lymphocyte-activation gene 3 (LAG-3) including a heavy chain variable region and a light chain variable region and inhibit the activity thereof. Thus it is expected to be useful for the development of immunotherapeutic agents for various disorders that are associated with LAG-3.

Monoclonal antibody specifically binding to LAG-3 and use thereof

The present invention relates to an antibody against delta-like 1 homolog () (DLK1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, an antibody drug conjugate (ADC) comprising the same, a pharmaceutical composition for treating cancer, a composition for diagnosing cancer, and a chimeric antigen receptor (CAR) and a T-cell engager comprising the same.

Antibody against human DLK1 and use thereof

The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 or a fragment thereof with a human antibody Fc region. Also provided are health functional foods containing a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 (delta-like 1 homolog) or a fragment thereof with a human antibody Fc region as an active ingredient.

Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of delta-like 1 homolog

Provided are a modified DKK2 polypeptide according to an aspect, a nucleic acid encoding the same, a preparation method thereof, and use thereof. Accordingly, a modified DKK2 protein having an additional glycosyl group or improved binding affinity for a substrate LRP6 may be efficiently prepared, thereby being used for promoting angiogenesis or preventing or treating vascular permeability-related diseases.

Modified DKK2 protein, nucleic acid encoding the same, preparation method thereof, and use thereof

The present invention relates to a TNF-&#x3b1; (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-&#x3b1; specific antibody, is a bispecific antibody that effectively binds to both TNF-&#x3b1; and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-&#x3b1;/CXCL10. A composition of the present invention comprises a TNF-&#x3b1;/CXCL-10 double targeting antibody which effectively binds to both TNF-&#x3b1; and CXCL10. The double targeting antibody of the present invention has excellent TNF-&#x3b1; inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-&#x3b1; or CXCL10 single targeting antibody. The composition of the present invention can be used in preventing or treating immunological disease.

Anti-TNF-&#x3b1;/CXCL10 double-targeting antibody and use thereof

Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.

Anti-c-Met antibody having HGF activity and use thereof

The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.

Myostatin inhibitor comprising extracellular water-soluble domains of DLK1 as active ingredient

The present invention relates to a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody. More specifically, the present invention relates to: a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody; a pharmaceutical composition for cancer treatment comprising the drug conjugate; and a cancer treatment method comprising a step in which the drug conjugate or pharmaceutical composition is administered to an individual.

Drug conjugate comprising drug linked to human c-Met antibody, and use therefor

Growing community of inventors

Daejeon, South Korea

Seok Ho Yoo